Clinical Biomarkers Market to Grow with a CAGR of 15.42% through 2030
Growing occurrences of infectious diseases and various types of
cancers to drive the clinical biomarkers market in the forecast period, 2026-2030.
According to TechSci Research report, “Clinical
Biomarkers Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2030”, the Global Clinical Biomarkers Market was valued at USD 16.27 billion in 2024 and is expected to reach USD 38.47 billion by 2030 with a CAGR of 15.42% during the forecast period. The
growing prevalence of infectious diseases and various type of cancer, rise in research
and development activities, and adoption of advanced technology are the primary
factors driving the demand for the global clinical biomarkers market. The increasing
demand for personalized treatment, surge in the number of patients, rising
healthcare burden, growing geriatric base, and rising funding for research and
technological development are expected to influence the market demand. Also, the
surge in number of strategies such as partnerships, collaborations, and product
launches undertaken by the market players are also a key factor for supporting
the growth of the clinical biomarkers market, globally.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Global Clinical Biomarkers Market"
The global clinical
biomarkers market is segmented into product, services, technology, clinical
area, application, end user, regional distribution and company.
Based on Service, the Genomic Biomarker Service category shows the fastest growth in the Global Clinical Biomarkers Market. The growing importance of genomics in precision medicine, drug discovery, and patient stratification is driving demand for genomic biomarker services at a rapid pace. Advances in next-generation sequencing (NGS), bioinformatics, and computational biology have made large-scale genomic analysis more accessible and cost-effective. For instance, according to the U.S. National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome has fallen from nearly USD 100 million in 2001 to less than USD 600 in 2023, making genomic biomarker testing widely feasible in both research and clinical applications. This cost reduction has enabled large-scale genomic studies, boosting the adoption of genomic biomarker services for disease risk prediction, therapeutic response evaluation, and drug safety profiling.
Based on the Region, Asia-Pacific shows the fastest growth in the Global Clinical Biomarkers Market. This rapid expansion is primarily driven by the rising burden of chronic and lifestyle-related diseases, coupled with increasing investments in healthcare infrastructure and research. According to the World Health Organization (WHO), noncommunicable diseases (NCDs) account for nearly 62% of all deaths in the Asia-Pacific region, with cardiovascular diseases, diabetes, and cancers being the leading causes. The growing patient population is creating strong demand for advanced diagnostic solutions such as biomarkers that can facilitate early detection, personalized treatment, and better disease management. Government support and policy initiatives in countries such as China, India, Japan, and South Korea are also accelerating growth. For instance, China’s government has prioritized precision medicine as part of its healthcare development plan, allocating over USD 9 billion by 2030 to precision medicine projects, including biomarker-based research. Similarly, India has expanded funding under the Department of Biotechnology (DBT) to strengthen genomics and biomarker research programs, while Japan has been at the forefront of integrating biomarker-based diagnostics into clinical practice, particularly for oncology and neurology. These government-backed efforts are boosting the adoption of biomarker-driven clinical trials and diagnostic tools in the region.
Major companies operating
in Global Clinical Biomarkers Market are:
- Agilent Technologies, Inc.
- Illumina, Inc.
- F. Hoffmann-La Roche AG
- QIAGEN NV
- PerkinElmer, Inc
- Thermo Fischer Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- NeoGenomics Laboratories, Inc.
- Charles River Laboratories International, Inc.
- Quest Diagnostics, Inc.
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“North America region dominates the market and is expected to maintain
its dominance in the coming years due to increasing prevalence of infectious diseases,
and various type of cancer, and rise in the R&D activities. The extensive
development in technology, high adoption rate of cancer genomics research, well-established
research infrastructure, strong presence of prominent players, and growing government
initiatives in the healthcare sector in the region are another key factor. Also,
increasing adoption of expansion strategies and rise in medical tourism in the
region are expected to propel the global clinical biomarkers market growth till
2030” said Mr. Karan Chechi, Research Director of TechSci Research, a
research based global management consulting firm.
“Clinical Biomarkers Market
- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented
By Product (Efficacy Biomarkers, Safety
Biomarkers, Validation Biomarkers), By Services (Genomic Biomarker Service,
Tissue Biomarker Service, Cell Service, Proteomics Service), By Technology
(Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry,
Enzyme-Linked Immunosorbent Assay, Others), By Clinical Area (Cancer Biomarker,
Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Others),
By Application (Translational Research v/s Clinical Diagnostics), By End User
(Biotechnology & Pharmaceutical Companies, Diagnostic Centers, Academic
& Research Institutions, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of global clinical
biomarkers market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in global clinical biomarkers market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com